Trial Profile
A Placebo-controlled, Randomized, Dose Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Ocular Doses of Pazopanib in Healthy Adult and Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2014 New trial record